Physician profile
Julia Cogburn
NPI 1245439702
$24,672.84
in general payments reported to CMS, 2019-2025
87 companies · $7,009 in 2025
The $7,009 reported for 2025 was more than what 78% of Medical Oncology providers received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,863 · 2020: $2,046 · 2021: $1,355 · 2022: $3,073 · 2023: $3,165 · 2024: $5,162 · 2025: $7,009.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $13K · Long Term Medical Supply Or Device Loan: $2,299 · Education: $22.38.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $13,014.71 |
| Long Term Medical Supply Or Device Loan | $2,299.02 |
| Education | $22.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $4,913.42 | 2019-2025 | |
| Genentech USA, INC. | $1,630.73 | 2019-2025 | Tecentriq, Polivy, Alecensa |
| Astrazeneca Pharmaceuticals Lp | $1,389.78 | 2019-2025 | Enhertu, Calquence, Imfinzi |
| Pfizer INC. | $1,285.79 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $1,018.40 | 2019-2025 | Opdivo, Opdualag, Reblozyl |
| Merck Sharp & Dohme LLC | $957.05 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Janssen Biotech, INC. | $933.18 | 2019-2025 | Darzalex, Tecvayli, Talvey |
| Celgene Corporation | $902.68 | 2019-2025 | Reblozyl, Pomalyst, Opdualag |
| Eisai INC. | $860.44 | 2019-2025 | |
| Daiichi Sankyo INC. | $855.40 | 2019-2025 | Enhertu, Datroway |
| Incyte Corporation | $643.59 | 2019-2025 | Monjuvi, Jakafi, Jakafi |
| Abbvie INC. | $607.02 | 2019-2025 | Venclexta |
| Glaxosmithkline, LLC. | $561.48 | 2021-2025 | Ojjaara, Zejula, Jemperli |
| Genzyme Corporation | $492.16 | 2019-2025 | |
| Seagen INC. | $459.66 | 2019-2023 | Padcev, Adcetris, Tivdak |
Show all 87 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $403.91 | 2019-2025 | Trodelvy |
| Tersera Therapeutics LLC | $363.92 | 2022-2025 | Zoladex |
| Bayer Healthcare Pharmaceuticals INC. | $305.65 | 2019-2025 | |
| Puma Biotechnology, INC. | $293.22 | 2019-2025 | Nerlynx |
| Lilly USA, LLC | $280.08 | 2019-2025 | Verzenio, Jaypirca, Retevmo |
| Regeneron Healthcare Solutions, INC. | $279.76 | 2021-2025 | Libtayo |
| Array Biopharma INC | $241.65 | 2019-2025 | Braftovi, Mektovi, Lorbrena |
| Amgen INC. | $224.41 | 2019-2022 | |
| Beone Medicines USA, INC. | $214.49 | 2025 | Tevimbra, Brukinsa |
| Pharmacyclics LLC, An Abbvie Company | $213.89 | 2019-2023 | Imbruvica |
| Rigel Pharmaceuticals, INC. | $212.31 | 2023-2025 | Tavalisse, Rezlidhia, Gavreto |
| Exelixis INC. | $207.53 | 2021-2025 | Cabometyx |
| Takeda Pharmaceuticals U.S.A., INC. | $193.49 | 2019-2024 | Fruzaqla, Alunbrig |
| Sirtex Medical INC | $188.99 | 2019-2024 | Sir-Spheres Microspheres |
| Boehringer Ingelheim Pharmaceuticals, INC. | $176.44 | 2019-2023 | Gilotrif |
| Pharmacosmos Therapeutics INC. | $154.54 | 2024-2025 | Monoferric, Cosela |
| Aadi Bioscience, INC. | $145.68 | 2024-2025 | Fyarro |
| Deciphera Pharmaceuticals INC. | $143.43 | 2021-2025 | Qinlock, Romvimza, Tgct |
| Stemline Therapeutics INC. | $141.97 | 2023-2025 | Orserdu |
| Mirati Therapeutics, INC. | $134.19 | 2023-2024 | Krazati |
| Astellas Pharma US INC | $133.60 | 2019-2024 | Padcev, Xospata |
| Sanofi US Services INC. | $131.90 | 2025 | |
| Beigene USA, INC. | $129.07 | 2022-2024 | Brukinsa |
| Immunogen, INC. | $128.36 | 2023 | Elahere |
| Alexion Pharmaceuticals, INC. | $127.84 | 2020-2025 | Ultomiris |
| Aveo Pharmaceuticals, INC. | $115.43 | 2022-2025 | Fotivda |
| Emd Serono, INC. | $101.99 | 2019-2025 | Bavencio |
| Clovis Oncology, INC. | $86.92 | 2019-2020 | |
| Tesaro, INC. | $86.70 | 2019 | |
| Jazz Pharmaceuticals INC. | $80.14 | 2022-2024 | |
| Iovance Biotherapeutics, INC. | $79.47 | 2025 | Amtagvi |
| Sobi, INC | $75.56 | 2022-2025 | |
| Kite Pharma, INC. | $69.07 | 2020-2023 | Yescarta |
| Csl Behring | $66.36 | 2022-2024 | Idelvion, Afstyla |
| Amag Pharmaceuticals, INC. | $65.87 | 2019-2022 | |
| Cti Biopharma Corp. | $60.31 | 2023 | Vonjo |
| Springworks Therapeutics, INC. | $55.03 | 2024 | Ogsiveo |
| Karyopharm Therapeutics INC. | $54.83 | 2020-2025 | Xpovio |
| Blueprint Medicines Corporation | $54.55 | 2024-2025 | Ayvakit |
| Legend Biotech USA INC. | $53.95 | 2024-2025 | Carvykti |
| Agios Pharmaceuticals, INC. | $53.87 | 2021-2025 | Pyrukynd |
| Myovant Sciences INC. | $50.49 | 2021-2022 | |
| Servier Pharmaceuticals LLC | $46.98 | 2024-2025 | |
| Janssen Pharmaceuticals, INC | $46.55 | 2019-2021 | |
| Myriad Genetic Laboratories, INC. | $42.18 | 2024 | Myrisk |
| Taiho Oncology, INC. | $40.90 | 2019-2024 | |
| Ipsen Biopharmaceuticals, INC | $40.90 | 2022-2025 | Onivyde, Somatuline Depot |
| Pharmaessentia USA Corporation | $40.68 | 2022-2025 | Besremi |
| Genmab U.S., INC. | $39.55 | 2023-2025 | Epkinly |
| Adc Therapeutics America, INC. | $36.70 | 2022-2023 | |
| Ge Healthcare | $36.38 | 2022 | |
| Sumitomo Pharma America, INC. | $34.03 | 2024-2025 | Orgovyx |
| Nanostring Technologies, INC. | $27.22 | 2019 | |
| Geron Corporation | $25.28 | 2025 | Rytelo |
| Telix Pharmaceuticals | $24.57 | 2023 | Illuccix |
| Delcath Systems | $23.22 | 2025 | Hepzato Kit |
| Foundation Medicine, INC. | $23.03 | 2023 | |
| Dendreon Pharmaceuticals LLC | $23.00 | 2022 | |
| Corcept Therapeutics | $22.25 | 2025 | Korlym |
| Syndax Pharmaceuticals, INC. | $21.45 | 2025 | |
| Azurity Pharmaceuticals, INC. | $19.15 | 2025 | Danziten |
| Acceleron Pharma, INC. | $18.37 | 2021 | |
| G1 Therapeutics, INC. | $17.31 | 2023 | Cosela |
| Morphosys, US INC. | $17.21 | 2023 | Monjuvi |
| West Therapeutics Development, LLC | $16.84 | 2020 | |
| Veracyte, INC. | $16.00 | 2020-2023 | |
| Teva Pharmaceuticals USA, INC. | $14.53 | 2019 | |
| Verastem, INC. | $14.35 | 2019 | |
| Acrotech Biopharma INC. | $14.25 | 2022 | |
| Medtronic, INC. | $14.05 | 2021 | |
| Supernus Pharmaceuticals, INC. | $12.86 | 2023 | Qelbree |
| Aurobindo Pharma USA, INC. | $11.41 | 2019 |
Drugs and devices associated with these payments
Kisqali $2,469Enhertu $736Reblozyl $723Tecentriq $532Lenvima $515Keytruda $496Zoladex $341Opdivo $309Lynparza $308Libtayo $261Jakafi $258Imbruvica $250Polivy $228Datroway $227Monjuvi $216Epkinly $215Calquence $215Elahere $214Tavalisse $212Ojjaara $207Rezlidhia $206Pluvicto $203Ibrance $202Gavreto $201Adcetris $199Ayvakit $186Darzalex $184Tevimbra $182Tukysa $177Braftovi $176Venclexta $175Imfinzi $171Cabometyx $164Mektovi $155Padcev $150Fyarro $146Orserdu $142Krazati $134Monoferric $134Bosulif $132Brukinsa $131Tecvayli $131Trodelvy $131Zejula $128Vonjo $117Lorbrena $115Verzenio $115Jaypirca $115Talvey $113Jemperli $112Elrexfio $109Qinlock $108Vitrakvi $101Stivarga $101Rybrevant $101Nerlynx $101Sarclisa $97.06Nubeqa $89.33Zynyz $87.13Tivdak $85.21Mekinist $83.76Fotivda $79.74Amtagvi $79.47Paxlovid $78.55Comirnaty $78.44Opdualag $77.90Carvykti $74.37Fabhalta $74.35Xofigo $70.63Scemblix $68.08Fruzaqla $67.48Ultomiris $64.72Pomalyst $61.78Lutathera $58.64Piqray $57.26Alunbrig $56.36Ogsiveo $55.03Besponsa $50.71Illuccix $49.14Romvimza $48.52Tibsovo $46.98Afstyla $46.08Idelvion $46.08Gilotrif $45.88Eliquis $44.23Myrisk $42.18Xtandi $41.68Xalkori $41.00Pyrukynd $40.88Welireg $40.28Xpovio $39.33Cosela $37.88Orgovyx $34.03Tecentriq Hybreza $29.74Alecensa $29.74Wayrilz $29.47Lonsurf $27.52Inqovi $27.52Rytelo $25.28Onivyde $25.16
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julia Cogburn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.